Non-invasive VNS Effects on Hyperarousal and Autonomic State in Patients with PTSD
Journal: Frontiers in Medicine (2017) Authors: Damon G. Lamb, Eric C. Porges, Greg F. Lewis and John B. Williamson Background: ...
This is Andy. Like many with PTSD, Andy wasn't satisfied with current treatment methods, so he enrolled in our pilot trial. This is his story.
The Phoenix® is not currently approved in the US nor is it for sale.
My wife says she has her husband back and our kids have their dad back
My therapist says I've completely changed
I feel like I have a healthy balance with everything that made me unbalanced before
The FDA requires a 50% responder rate and an average 6 pt reduction in the CAPS-5.
We are happy to report that the Phoenix exceeded these requirements and provided an average 18.4 pt reduction in CAPS-5, with only 1 non-responder and 1 non-compliant participant. These results were statistically and clinically significant with a p-value of .0100 and a 95%CI: 0.57, 0.98.
The Promis-29 looks at 7 aspects of quality of life and compares responses to the general population to determine severity of responses.